

Yongrong Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6508278/publications.pdf>

Version: 2024-02-01

23
papers

709
citations

687363

13
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

831
citing authors

#	ARTICLE	IF	CITATIONS
1	The development of live biotherapeutics against <i>Clostridioides difficile</i> infection towards reconstituting gut microbiota. <i>Gut Microbes</i> , 2022, 14, 2052698.	9.8	9
2	Establishment of a gnotobiotic pig model of <i>Clostridioides difficile</i> infection and disease. <i>Gut Pathogens</i> , 2022, 14, .	3.4	1
3	Spray layering of human immunoglobulin G: Optimization of formulation and process parameters. <i>International Journal of Pharmaceutics</i> , 2021, 610, 121238.	5.2	4
4	A probiotic yeast-based immunotherapy against <i>Clostridioides difficile</i> infection. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	61
5	Structure of the full-length <i>Clostridium difficile</i> toxin B. <i>Nature Structural and Molecular Biology</i> , 2019, 26, 712-719.	8.2	59
6	Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of <i>C. difficile</i> toxin B. <i>PLoS Biology</i> , 2019, 17, e3000311.	5.6	24
7	Mice with Inflammatory Bowel Disease are Susceptible to <i>Clostridium difficile</i> Infection With Severe Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 573-582.	1.9	29
8	Cysteine Protease-Mediated Autocleavage of <i>Clostridium difficile</i> Toxins Regulates Their Proinflammatory Activity. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2018, 5, 611-625.	4.5	14
9	The role of purified <i>Clostridium difficile</i> glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model. <i>Anaerobe</i> , 2017, 48, 249-256.	2.1	9
10	A Multiparticulate Delivery System for Potential Colonic Targeting Using Bovine Serum Albumin as a Model Protein. <i>Pharmaceutical Research</i> , 2017, 34, 2663-2674.	3.5	11
11	Newly identified bacteriolytic enzymes that target a wide range of clinical isolates of <i>Clostridium difficile</i> . <i>Biotechnology and Bioengineering</i> , 2016, 113, 2568-2576.	3.3	20
12	Pathogenic effects of glucosyltransferase from <i>Clostridium difficile</i> toxins. <i>Pathogens and Disease</i> , 2016, 74, ftw024.	2.0	4
13	Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from <i>Clostridium difficile</i> infection. <i>Pathogens and Disease</i> , 2016, 74, ftw078.	2.0	16
14	Masking autoprocessing of <i>Clostridium difficile</i> toxin A by the C-terminus combined repetitive oligopeptides. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 259-263.	2.1	13
15	Mechanisms of Protection against <i>Clostridium difficile</i> Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab. <i>Infection and Immunity</i> , 2015, 83, 822-831.	2.2	88
16	Glucosyltransferase activity of <i>Clostridium difficile</i> Toxin B is essential for disease pathogenesis. <i>Gut Microbes</i> , 2015, 6, 221-224.	9.8	17
17	Critical Roles of <i>Clostridium difficile</i> Toxin B Enzymatic Activities in Pathogenesis. <i>Infection and Immunity</i> , 2015, 83, 502-513.	2.2	31
18	A Segment of 97 Amino Acids within the Translocation Domain of <i>Clostridium difficile</i> Toxin B Is Essential for Toxicity. <i>PLoS ONE</i> , 2013, 8, e58634.	2.5	22

#	ARTICLE	IF	CITATIONS
19	Systemic Dissemination of Clostridium difficile Toxins A and B Is Associated With Severe, Fatal Disease in Animal Models. Journal of Infectious Diseases, 2012, 205, 384-391.	4.0	76
20	Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Science China Life Sciences, 2012, 55, 800-806.	4.9	20
21	Retargeting Clostridium difficile Toxin B to Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic Biomolecules to Treat Botulism. Journal of Toxicology, 2012, 2012, 1-9.	3.0	7
22	A Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection. Infection and Immunity, 2012, 80, 2678-2688.	2.2	81
23	Mouse Relapse Model of Clostridium difficile Infection. Infection and Immunity, 2011, 79, 2856-2864.	2.2	92